1. Home
  2. |Insights
  3. |Commission In Limbo: SCOTUS Puts CPSC Commissioners Back Out of Action

Commission In Limbo: SCOTUS Puts CPSC Commissioners Back Out of Action

Client Alert | less than 1 min read | 07.24.25

In May 2025, the Trump Administration, asserting Executive authority, terminated the three Democratic Commissioners of the Consumer Product Safety Commission. On June 13, 2025, a Maryland district court aborted the without-cause termination while a legal challenge proceeds, leaving the Commissioners in place.

No longer. On July 23, 2025, the Supreme Court granted an emergency request and stayed the district court’s blocking order. The six-Justice majority reasoned that the harm to the government from the stay order outweighs a Commissioner’s inability to perform his or her statutory duty.

While the majority ruling was unsigned, three Justices by name dissented, declaring this an unwarranted use of the Court’s stay authority.

Crowell will be monitoring developments as they unfold. 

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights